
NGeneBio
NGS panel BRCAaccuTest PLUS
NGS test of hereditary breast and ovarian cancer: BRCA1 and BRCA2 genes
The BRCAaccuTest PLUS NGS test detects BRCA1 and BRCA2 gene mutations from blood and FFPE tissue samples, helping to assess the risk of hereditary breast and ovarian cancer.
Request a quotationThe next-generation sequencing test system identifies pathogenic variants in BRCA1 and BRCA2 genes in genomic DNA from blood or tumor FFPE tissue samples. Sequencing is performed on Illumina MiSeq devices with an average coating of about 200× for germinal and 1,000× for somatic samples. NGeneAnalySys, which forms a clinical report.
The BRCAaccuTest PLUS panel covers the BRCA1 and BRCA2 genes. Diagnostic efficacy was confirmed in a sample of 108 samples - the results are more than 99% matched.
precision
- Average sequencing coverage of about 200× for germinal and 1,000× for somatic samples
- Diagnostic match of results confirmed on 108 samples - more than 99%
Clinical application
- Determination of variants in BRCA1 and BRCA2 genes from genomic DNA from blood or FFPE tissue
- The results are used to assess the risk of inherited breast and ovarian cancer
Platform
- Sequencing is performed on Illumina MiSeq instruments
- Compatible with NGeneAnalySys for interpreting options and reporting
Panel
| Parameter | BRCAaccuTest PLUS |
|---|---|
| Genes | BRCA1, BRCA2 |
| Type of sample | genomic DNA from blood or FFPE tissue |
| Average coverage | ~200× (germinal samples); ~1,000× (somatic samples) |
| Clinical validation | 108 samples, diagnostic match over 99% |
Platform and software
| Parameter | BRCAaccuTest PLUS |
|---|---|
| Sequencing | Illumina MiSeq |
| Analysis | NGeneAnalySys |
Certification
| Parameter | BRCAaccuTest PLUS |
|---|---|
| Status | CE-IVD |
